Navigation Links
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Date:6/2/2009

e on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
2. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
3. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
4. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
5. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
6. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
7. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
8. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
9. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
10. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
11. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Innovation is more urgent than ever. Radical business ... world and transforming global markets in industry after ... care, disruption is constantly underway. , As technology ... the foundations of established business models, large-scale innovation ... the next wave of mega-change. , This wave ...
(Date:2/26/2015)... Grove, IL (PRWEB) February 26, 2015 ... month for the development of oncology drug substances. , ... start up of their new Potent Compound Suite (PCS) ... operating a 36,000 square foot, cGMP facility in Morton ... molecule cGMP manufacturing of potent compounds up to about ...
(Date:2/26/2015)... 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... the Cowen 35 th Annual Health Care Conference on ... Boston .  Lexicon management will provide an overview ... webcast of the presentation will be available through Lexicon,s website ... will be available at www.lexpharma.com until April 3, ...
(Date:2/26/2015)... Texas , Feb. 26, 2015 ... two posters, at the 2015 Genitourinary Cancers Symposium ... highlight the clinical utility of tumor profiling. Both ... comprehensive tumor profiling service, to identify biomarkers that ... prostate cancer and small cell bladder cancer (SCBC). ...
Breaking Biology Technology:One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Regis Extends cGMP Services to Oncology Market 2Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5
... (Nasdaq: PRXL ) today announced its financial ... For the three months ended December 31, ... $304.4 million, compared with $284.7 million in the prior ... movements of $4.8 million, revenue increased 8.6%.  As reported ...
... Direct, a wholly owned subsidiary of Medco Health Solutions, ... provider of guidance and decision support for genomic medicine, ... Atlantic Health of Morristown, New Jersey, Crittenton Hospital Medical ... Chicago, Illinois, have joined the Genomic Medicine Network to ...
... SHANGHAI, Jan. 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, ... the leading developer, manufacturer and distributor of probiotics products ... call at 08:00 a.m. Eastern Time/09:00 p.m. Beijing Time ... year 2011 third quarter financial results for the period ...
Cached Biology Technology:PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 10PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results 11Four Community Hospitals Join DNA Direct's Genomic Medicine Network 2Four Community Hospitals Join DNA Direct's Genomic Medicine Network 3China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9 2
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... and Roquette Frres have signed a licensing deal ... substance used in plastics, textiles, drugs and solvents ... one of the world,s most advanced starch and ... metabolic engineering technologies, which can produce bio-based succinic ...
... the first computer model that simulates the global ... have been analyzed by a team of scientists ... the University of Hawai`i at Mānoa, Japan-Agency for ... University of Tokyo. The model, called the ...
... Trust has announced a 4.1 million investment in ... "chemical probes" for 25 proteins involved in epigenetic ... domain with no restriction on use. Early stage information ... with the tradition of keeping such data confidential. ...
Cached Biology News:'Green' chemicals closer to market 2International public-private partnership offers new paradigm for medicinal chemistry 2International public-private partnership offers new paradigm for medicinal chemistry 3
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: